Divozilimab vs Ublituximab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: CD20 · full Multiple Sclerosis pipeline
Divozilimab · Ivlizi
Marketed by Biocad
NCT05385744 · Phase 3 · completed
Randomized, double-blind, active-controlled Phase 3 trial (338 patients randomized 1:1) showing superior relapse reduction vs teriflunomide (PMID 38676683).
Reported efficacy
Annualized Relapse Rate (ARR): Annualised relapse rate over 2 years (100 weeks): divozilimab 0.057 vs teriflunomide 0.164 (met)
Result source: NCT05385744
Ublituximab · Briumvi
Marketed by TG THERAPEUTICS, INC. and partners
NCT03277261 · Phase 3 · completed
This was a randomized, quadruple-masked, active-controlled trial of 549 participants, with ublituximab and teriflunomide administered alongside matching placebos. The primary clinical endpoint was met: ublituximab produced a significantly lower annualized relapse rate than teriflunomide through 96 weeks (p<0.0001).
Next expected readout: January 2027 · NCT05877963 (registry estimate)
Reported efficacy
Annualized Relapse Rate (ARR) (Up to 96 weeks): Annualized Relapse Rate (ARR) (Up to 96 weeks): Ublituximab + Oral Placebo 0.091 relapses per participant-years (95% CI 0.049 to 0.169) vs Teriflunomide + IV Placebo 0.178 relapses per participant-years (95% CI 0.109 to 0.291) (met)
Result source: NCT03277248
Results for Multiple Sclerosis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Divozilimab | Ublituximab |
|---|---|---|
| Annualised relapse rate | —Not posted · NCT05385744 | 0.1 vs 0.2vs TeriflunomideNCT032772611 other result
|
| Free of 3-month confirmed disability progression (%) | —Not posted · NCT05385744 | —Trial running · NCT07220252 |
| New or enlarging T2 lesions | —Not posted · NCT05385744 | —Trial running · NCT07220252 |
Annualised relapse rate
- Divozilimab
- —Not posted · NCT05385744
- Ublituximab
- 0.1 vs 0.2vs TeriflunomideNCT03277261
1 other result
- 0.1 vs 0.2 NCT03277248
Free of 3-month confirmed disability progression (%)
- Divozilimab
- —Not posted · NCT05385744
- Ublituximab
- —Trial running · NCT07220252
New or enlarging T2 lesions
- Divozilimab
- —Not posted · NCT05385744
- Ublituximab
- —Trial running · NCT07220252
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Divozilimab: 1 of 5 rows · Ublituximab: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Divozilimab | Ublituximab |
|---|---|---|
| Annualized Relapse event rate · per year No placebo or comparator arm | 0.05 per yeara,b,c,d NCT05385744 · Phase 3 · sponsor-reported, not registry data | 0.28 per year @ 48wke,a,b,c,d NCT02738775 · Phase 2 · registry result, not featured evidence show 5 more doses0 per year @ 48wk NCT02738775 · Phase 2 · registry result, not featured evidence 0.14 per year @ 48wk NCT02738775 · Phase 2 · registry result, not featured evidence 0.14 per year @ 48wk NCT02738775 · Phase 2 · registry result, not featured evidence 0 per year @ 48wk NCT02738775 · Phase 2 · registry result, not featured evidence 0 per year @ 48wk NCT02738775 · Phase 2 · registry result, not featured evidence |
| Dropout rate | — | 12.4%f NCT03277261 · Phase 3 · combination show 7 more results6.6% NCT03277248 · Phase 3 · combination 0%Cohort 1 NCT02738775 · Phase 2 · registry result, not featured evidence 25%Cohort 2 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 3 NCT02738775 · Phase 2 · registry result, not featured evidence 11.1%Cohort 4 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 5 NCT02738775 · Phase 2 · registry result, not featured evidence 12.5%Cohort 6 NCT02738775 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | — | 6.2%f NCT03277261 · Phase 3 · combination show 7 more results1.1% NCT03277248 · Phase 3 · combination 0%Cohort 1 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 2 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 3 NCT02738775 · Phase 2 · registry result, not featured evidence 11.1%Cohort 4 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 5 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 6 NCT02738775 · Phase 2 · registry result, not featured evidence |
| Serious AEs | — | 11.4%f NCT03277261 · Phase 3 · combination show 7 more results10.3% NCT03277248 · Phase 3 · combination 0%Cohort 1 NCT02738775 · Phase 2 · registry result, not featured evidence 12.5%Cohort 2 NCT02738775 · Phase 2 · registry result, not featured evidence 25%Cohort 3 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 4 NCT02738775 · Phase 2 · registry result, not featured evidence 0%Cohort 5 NCT02738775 · Phase 2 · registry result, not featured evidence 25%Cohort 6 NCT02738775 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | — | show 7 more resultsback pain 37.5% (placebo 0%) headache 25% (placebo 15.4%) hypoaesthesia 25% (placebo 7.7%) NCT02738775 · Phase 2 · registry result, not featured evidence dizziness 37.5% (placebo 23.1%) fatigue 37.5% (placebo 38.5%) headache 37.5% (placebo 15.4%) NCT02738775 · Phase 2 · registry result, not featured evidence arthralgia 25% (placebo 7.7%) diarrhoea 25% (placebo 0%) fatigue 25% (placebo 38.5%) NCT02738775 · Phase 2 · registry result, not featured evidence fatigue 50% (placebo 38.5%) nasopharyngitis 37.5% (placebo 0%) sinusitis 37.5% (placebo 15.4%) NCT02738775 · Phase 2 · registry result, not featured evidence dysphagia 37.5% (placebo 15.4%) infusion related reaction 37.5% (placebo 23.1%) throat irritation 37.5% (placebo 15.4%) NCT02738775 · Phase 2 · registry result, not featured evidence nausea 62.5% (placebo 15.4%) dizziness 37.5% (placebo 23.1%) fatigue 37.5% (placebo 38.5%) NCT02738775 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 3 versus Phase 2.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ublituximab
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 11 more results
show 11 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Divozilimab's landscape · Ublituximab's landscape